XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate cancer ...
Bayer announced today that new research findings on Xofigo ® (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from ...
Algeta said today it received a “preliminary acquisition proposal” from Bayer worth NOK 14.8 billion ($2.42 billion), as the German pharma and chemical conglomerate seeks to acquire its partner in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results